Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.

Cancer cell - 9 Nov 2020

Passaro Antonio, Stenzinger Albrecht, Peters Solange

Abstract excerpt

A recent study in The Lancet Oncology reports that high tumor mutational burden (TMB) is associated with response to anti-PD-1 pembrolizumab, leading to the second FDA approval of a tissue-agnostic predictive biomarker for immunotherapy in solid tumors. This is a step forward in realizing the full potential of cancer immunotherapy.

Topics

Join the communities discussing this publication.

Antibodies, Monoclonal, Humanized
Biomarkers, Tumor
Cancer Immunotherapy and Biomarkers
Clinical Trials as Topic
Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Treatment Outcome

Source

Identifiers

PMID: 33171127
DOI: 10.1016/j.ccell.2020.10.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.PMID 33171127Read ↗

Tumor Mutational Burden as a Predictive Biomarker in Solid TumorsSemantic proximity Read ↗

Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?Semantic proximity Read ↗

Tumour mutational burden: clinical utility, challenges and emerging improvements.Semantic proximity Read ↗

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?Semantic proximity Read ↗

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.Semantic proximity Read ↗

Evaluating Tumour Mutational Burden as a Key Biomarker in Personalized Cancer Immunotherapy: A Pan-Cancer ApproachSemantic proximity Read ↗

The status of tumor mutational burden and immunotherapySemantic proximity Read ↗

Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology.Semantic proximity Read ↗

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicSemantic proximity Read ↗

Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities.Semantic proximity Read ↗

Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab.Semantic proximity Read ↗

Is tumor mutational burden predictive of response to immunotherapy?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.